Aligos Therapeutics (NASDAQ:ALGS) Releases Quarterly Earnings Results, Misses Expectations By $0.95 EPS

Aligos Therapeutics (NASDAQ:ALGS) released its earnings results on Thursday. The company reported ($3.04) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($2.09) by ($0.95), Zacks reports. The company had revenue of $0.74 million for the quarter, compared to analyst estimates of $0.50 million. Aligos Therapeutics had a negative net margin of 2,337.24% and a negative return on equity of 22.41%.

Aligos Therapeutics Trading Down 0.4%

NASDAQ ALGS traded down $0.03 during trading hours on Friday, hitting $7.07. The company’s stock had a trading volume of 76,332 shares, compared to its average volume of 148,287. The company has a market capitalization of $43.48 million, a PE ratio of -0.36 and a beta of 2.76. Aligos Therapeutics has a 52 week low of $3.76 and a 52 week high of $46.80. The company’s 50-day simple moving average is $9.70 and its two-hundred day simple moving average is $8.17.

Analysts Set New Price Targets

ALGS has been the topic of a number of research analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Aligos Therapeutics in a research report on Wednesday, October 8th. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Aligos Therapeutics in a research report on Friday, September 12th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $50.00.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Geode Capital Management LLC increased its stake in shares of Aligos Therapeutics by 21.3% during the 2nd quarter. Geode Capital Management LLC now owns 34,048 shares of the company’s stock worth $246,000 after purchasing an additional 5,978 shares during the last quarter. XTX Topco Ltd bought a new position in Aligos Therapeutics during the second quarter valued at $100,000. Vanguard Group Inc. increased its position in Aligos Therapeutics by 22.8% in the third quarter. Vanguard Group Inc. now owns 171,689 shares of the company’s stock worth $1,683,000 after buying an additional 31,913 shares during the last quarter. Finally, Woodline Partners LP bought a new stake in shares of Aligos Therapeutics in the first quarter valued at $2,602,000. Institutional investors own 60.43% of the company’s stock.

About Aligos Therapeutics

Aligos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH).